The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A system for charged particle therapy verification, comprising a first detector configured for detection of secondary particles emitted from a target irradiated with a charged particle beam, wherein the detector is configured to cause at least two consecutive elastic scatters in the detector for secondary particles of fast neutrons and two consecutive incoherent scatters followed by a third scatter, being one of: photoelectric effect, incoherent scatter or pair production for secondary particles of prompt gamma-ray types.
A large area microwave plasma chemical vapour deposition, LA MPCVD reactor apparatus and method for large area microwave chemical vapour deposition, comprising a reactor chamber adapted to provide a plasma region in an interior of the reactor chamber by electromagnetic energy at a first frequency, and a CRLH waveguide section adapted to operate with an infinite wavelength at the first frequency and having in a wall a coupler means arranged to couple electromagnetic energy from an interior of the CRLH waveguide section to the interior of the reactor chamber.
COMBINATION THERAPY INCLUDING BETA-SITOSTEROL IN COMBINATION WITH AT LEAST ONE OF A BRAF INHIBITOR, A MEK INHIBITOR AND AN ERK INHIBITOR AND METHODS AND USE THEREOF
The present invention relates in a first aspect to a pharmaceutical composition comprising beta-sitosterol or a homolog thereof in combination with a BRAF inhibitor and/or a MEK inhibitor and/or an ERK inhibitor. In particular, the present invention relates to a combination of the beta-sitosterol in combination with a BRAF inhibitor like vemurafenib, PLX4720 or dabrafenib or the MEK inhibitor trametinib. The composition is particularly useful in the treatment of cancer including metastatic cancer for example by oral or intravenous administration of both. The beta-sitosterol and the at least one of the BRAF inhibitor and/or MEK inhibitor and/or an ERK inhibitor being administered simultaneously, separately or sequentially. In a further aspect, a method of treating individuals suffering from cancer using the pharmaceutical composition according to the present invention is disclosed.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
In a first aspect, the present invention relates to an antibody directed against the alpha-11 integrin subunit, in particular, said antibody is an antibody binding the same epitope as the antibody 203 E1H5 produced by the hybridoma deposited as DSM ACC3318 or binding to the same epitope of the alpha-11 integrin subunit as bound by 234 H11E8 produced by the hybridoma deposited as DSM ACC3319. Further, the present invention relates to a pharmaceutical composition containing the antibodies according to the present invention as well as the use of the antibody or the pharmaceutical composition, accordingly, in treating or preventing fibrosis, cancer, scleroderma or excessive scarring observed in hypertrophic scars and keloids. Finally, the present invention relates to a kit for treating or preventing cancer, fibrosis or scleroderma as well as for preventing excessive scarring in wound healing comprising the antibody according to the present invention or the pharmaceutical according to the present invention.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
In a first aspect, the present invention relates to an antibody directed against the alpha-11 integrin subunit, in particular, said antibody is an antibody binding the same epitope as the antibody produced by the hybridoma deposited as DSM ACC3320. Further, the present invention relates to a method for detecting the alpha-11 integrin subunit in a sample. In particular, the antibody according to the present is an anti- body suitable for use in samples being cryopreserved and cryosectioned or formaldehyde fixed and paraffin embedded. The present invention relates further to a kit for detecting the alpha-11 integrin subunit containing the antibody according to the present invention. Finally, the present invention provides the antibody in a humanized form. The antibody, in particular, in its humanized forms are useful for antibody drug conjugates.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to compounds having the formula [Co-enzyme A or analogue thereof]-Z1-Z2-Z3-Z4, wherein Z1 is a linker, Z2 and Z3 are peptides or peptide-based moieties, and Z4 is a C-terminal group. The invention also provides pharmaceutical compositions comprising compounds of the invention, and their uses for the treatment of cancer, wound healing and nerve regeneration, inter alia.
C07K 5/113 - Tetrapeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
12.
METHOD FOR PRODUCING AN ICING PROTECTED ARRANGEMENT AND ICING PROTECTED ARRANGEMENT
An Icing protected arrangement (10), comprising a substrate(11)coated by an anti- icing coating (12), is capable to at least reduce the need for additional deicing provisions like heating or spraying with deicing solutions, if said anti-icing coating (12) comprising a fluorinated graphene layer (15).
C23C 16/01 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes on temporary substrates, e.g. on substrates subsequently removed by etching
C09K 3/18 - Materials not provided for elsewhere for application to surface to minimize adherence of ice, mist or water theretoThawing or antifreeze materials for application to surfaces
C23C 16/02 - Pretreatment of the material to be coated
The present invention relates to compounds of formula (I) as defined in the specification for use as pharmacological chaperones having a stabilizing effect on phenylalanine hydroxylase (PAH) for the treatment of hyperphenylalaninemia (HPA), in particular phenylketonuria (PKU). The compounds include trimethoprim and analogues and derivatives thereof.
3, . . . ) which give the mutual matching of the input data and the modelled data, and model probabilities of the predicted model parameters are calculated in dependency on the probability distribution functions.
The present invention relates to sapphire substrates having anti-fouling properties, to methods for their preparation and to their use as optical components in devices which transmit or receive light. The sapphire substrates have a micropatterned surface which comprises a plurality of sapphire pillars which project from the surface. The pillars have an aspect ratio less than or equal to about 1.0, and the ratio of the spacing between adjacent pillars to the pillar height is greater than or equal to about 0.5.
A scaffold (12) for tissue engineering comprises an inner portion (14), an outer portion (16), and a base portion (22) connecting the inner portion and the outer portion. The inner portion (14) comprises a channel (18) surrounded by a first set of one or more walls. The outer portion (16) comprises a second set of one or more walls. The portions are arranged such that the second set of one or more walls substantially surrounds the first set of one or more walls with a spacing between the first and second sets of walls defining a cavity (20) between the inner portion (14) and the outer portion (16). The inner portion (14) and the outer portion (16) may have different shapes; and/or the scaffold (12) may further comprise a filler material in the cavity (20) defined between the inner and outer portions.
The present invention refers to novel ruthenium-based catalysts for olefin metathesis reactions, particularly to fast initiating catalysts having stereoselective properties. In olefin metathesis reactions, the disclosed catalysts provide a high catalytic activity combined with the capability to generate higher yields of the olefin metathesis product.
A method of designing a neutral-beam microscope (1) is disclosed. The neutral-beam microscope comprises a neutral-particle source, arranged to emit neutral particles along a path towards a sample region. A skimmer (3) and an aperture-bearing member (5), such as a pinhole or a zone plate, are located along the path. The method comprises calculating (i) a diameter for the skimmer, (ii) a diameter for the aperture (6) of the aperture-bearing member, and (iii) a distance between the skimmer and the aperture, by solving an intensity-optimisation problem for the neutral-beam microscope having a predetermined resolution.
G01N 23/22 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material
G21K 1/02 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diaphragms, collimators
H05H 3/02 - Molecular or atomic-beam generation, e.g. resonant beam generation
The present invention provides a method for the treatment of a tumour in a subject, said method comprising administering (i) an autologous immature dendritic cell, or a precursor thereof, and (ii) an immune cell checkpoint inhibitor to said subject subsequent to the at least partial ablation of said tumour in said subject, wherein the administration of said autologous immature dendritic cells, or a precursor thereof, and said immune cell checkpoint inhibitor is local to the site of the ablated tumour or part thereof. The invention further provides a product containing an autologous immature dendritic cell, or a precursor thereof, and an immune cell checkpoint inhibitor as a combined preparation for separate, simultaneous or sequential use in a method for the treatment of a tumour in a subject, said method comprising administering (i) the autologous immature dendritic cell, or a precursor thereof, and (ii) the immune cell checkpoint inhibitor to said subject subsequent to the at least partial ablation of said tumour in said subject, wherein the administration of said autologous immature dendritic cells, or a precursor thereof, and said immune cell checkpoint inhibitor is local to the site of the ablated tumour or part thereof.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to the medicinal use of small organic compounds, in particular amide and urea derivatives, for the treatment of congenital disorders of glycosylation, and in particular PMM2 congenital disorder of glycosylation.
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07C 275/30 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
UNIVERSITY OF NEW SOUTH WALES INNOVATIONS (Australia)
Inventor
Kellmann, Ralf
Neilan, Brett
Abstract
The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions.
The invention provides a method of improving flesh pigmentation in a salmonid fish, said method comprising the step of feeding to said fish a fish bone hydrolysate material or feed composition containing said material. The invention further provides a process for hydrolysing fish bone comprising subjecting a raw material which comprises at least a proportion of fish bone to acid hydrolysis in the presence of sulphuric acid.
A23J 1/04 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from fish or other sea animals
A23J 1/10 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from hair, feathers, horn, skins, leather, bones, or the like
A23K 10/22 - Animal feeding-stuffs from material of animal origin from fish
A23K 10/26 - Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin
A23K 20/179 - Colouring agents, e.g. pigmenting or dyeing agents
A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
27.
WNT/BETA-CATENIN SIGNAL TRANSDUCTION INHIBITORS AND THEIR USE IN TREATMENT OR PREVENTION OF DISEASES AND CONDITIONS LINKED WITH SAID TRANSDUCTION
In the invention provides a WNT/β-catenin signal transduction inhibitor selected from (i) axitinib, (ii) pazopanib, (iii) orlistat, (iv) topotecan, (v) pharmaceutically effective substitution derivatives thereof, or (vi) pharmaceutically acceptable salts, or solvates or hydrates thereof, diastereoisomers, tautomers, enantiomers, and prodrugs and active metabolites thereof,for use in the treatment or prevention of a disease or condition in which WNT/β-catenin signal transduction is a contributing factor and for use in a method for the immunotherapy of a hyperproliferative or neoplastic disease or condition in a subject in which DCs are administered to the subject. The invention further provides an in vitromethod for diagnosing WNT/β- catenin dependent cancers, said method comprising (i) contacting a sample of cells from a test cancer with one or more of the WNT/β-catenin signal transduction inhibitors disclosed herein,and (ii) assessing the effects of said inhibitor on said sample.
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to compounds of formula (I) as defined in the specification for use as pharmacological chaperones having a stabilizing effect on phenylalanine hydroxylase (PAH) for the treatment of hyperphenylalaninemia (HPA), in particular phenylketonuria (PKU). The compounds include trimethoprim and analogues and derivatives thereof.
A method of predicting model parameters (R1, R2, R3, · · · ) of a geological formation under investigation, wherein said geological formation is distinguished by reservoir parameters including observable data parameters and the model parameters (R1, R2, R3, · · · )to be predicted, comprises the steps of calculating at least one model constraint (M1, M2, M3,... ) of the model parameters (R1, R2, R3, · · · ) by applying at least one rock physics model (f1, f2, f 3,...) on the model parameters (R1, R2, R3, · · · ), said at least one model constraint (M1, M2, M3,... ) including modelled data of at least one of the data parameters, and applying an inverse model solver process on observed input data (d1, d2, d3,... ) of at least one of the data parameters, including calculating predicted model parameters, which comprise values of the model parameters (R1, R2, R3, · · · ) which give a mutual matching of the in- put data and the modelled data, wherein the modelled data are provided with probability distribution functions, the inverse model solver process is conducted based on the probability distribution functions, wherein multiple predicted values of the model parameters are obtained comprising values of the model parameters (R1, R2, R3, · · · ) which give the mutual matching of the input data and the modelled data, and model probabilities of the predicted model parameters are calculated in dependency on the probability distribution functions.
The present invention refers to novel ruthenium-based catalysts for olefin metathesis reactions, particularly to fast initiating catalysts having stereoselective properties. In olefin metathesis reactions, the disclosed catalysts provide a high catalytic activity combined with the capability to generate higher yields of the olefin metathesis product.
INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) (France)
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (France)
BERGEN TEKNOLOGIOVERFORING AS (Norway)
Inventor
Fouilloux-Meugnier, Emmanuelle
Vidal, Hubert
Ruzzin, Jérôme
Abstract
The present invention relates to a FGF19 polypeptide for its use as an agent increasing muscle fibers size, in the prevention and/or treatment of muscle atrophy in a mammal body.
The Administrators of the Tulane Educational Fund (USA)
Inventor
Puntervoll, Pål
Sommerfelt, Halvor
Clements, John
Nataro, James P.
Zhang, Weiping
Taxt, Arne M.
Abstract
E coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant comprises a mutation selected from the group consisting of: A14H, A14T and N12T.
The present invention refers to novel ruthenium- and osmium-based catalysts for olefin metathesis reactions, particularly to catalysts having stereoselective properties. Z-selectivity is obtained by utilizing two mono-anionic ligands of very different steric requirement. In olefin metathesis reactions these catalysts selectively provide the Z-isomer of disubstituted olefinic products even in presence of air or of acids.
C08F 4/80 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from metals not provided for in group selected from iron group metals or platinum group metals
C07C 6/04 - Metathesis reactions at an unsaturated carbon-to-carbon bond at a carbon-to-carbon double bond
C07C 67/475 - Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
C07F 7/08 - Compounds having one or more C—Si linkages
34.
CYCLIC PHOSPHORIC ACID DERIVATIVE FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME
The present invention relates in first aspect to a cyclic phosphoric acid derivative for use in the treatment of chronic fatigue syndrome,also known myalgic encephalomyelitis. In particular, the present invention relates to the use of a pharmaceutical composition containing the cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis in a subject afflicted with said disease. In a further aspect, the present invention relates to a combination of the cyclic phosphoric acid derivative as defined herein with a B-cell depleting agent for use in the treatment of chronic fatigue syndrome. The combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the present invention relates to a method for treating chronic fatigue syndrome comprising the step of administering the cyclic phosphoric acid derivative to a subject afflicted therewith, optionally, in combination with a B-cell depleting agent.
Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A method of processing three-dimensional image data for volume-rendering from a viewpoint is described. Lower- and upper-bound-generating functions are used (7) to determine whether, across all possible values for the image voxels between respective lower and upper bounds, for each voxel (i) the voxel may be at least partially opaque under the opacity transfer function (8); and (ii) the voxel may be unoccluded from the viewpoint (9). A predetermined processing operation is then applied to these potentially-visible voxels, for which both determinations hold true (10) and the processed voxels may be rendered (1 1). The bound-generating functions and the processing operation are such that, for any three-dimensional image data, the value of a voxel after the processing operation will necessarily lie between the lower and upper bounds for that voxel.
The invention provides novel phenazine derivatives of formula I, methods for their preparation and their medical use, in particular as anti-neoplastic agents and anti-infective agents. The invention further relates to novel methods for the preparation of known iodinin and myxin. In formula I R1 to R7 are each independently i.a. hydrogen or alkyl, L is either a direct bond or a linker, and X is a functional group or a biocompatible polymer.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
The present invention relates in a first aspect to a therapeutically effective amount of a stimulator of the soluble guanylate cyclase and/or of an activator of the soluble guanylate cyclase for use in the treatment of chronic fatique syndrome (CFS) in a patient in need thereof. In a further aspect, the present invention relates to a combination of the stimulator and/or activator of the soluble guanylate cyclase with a B-cell depleting agent in the treatment of chronic fatique syndrome. In addition, a combination of stimulator and/or activator of the soluble guanylate cyclase with B-Cell depleting agent is described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 43/00 - Drugs for specific purposes, not provided for in groups
Animal feeds and feed components are provided which comprise tunicate material. The tunicate material may be whole tunicate, e.g. washed and/or dried, or a tunicate extract. Preferred tunicate extracts include protein- and/or lipid-enhanced extracts. Also provided are uses of tunicates and tunicate extracts as, or in, animal feeds and methods for feeding animals, e.g. fish, comprising administering feeds containing tunicate material.
The present invention relates to methods for detecting pyrethroid resistance in crustaceans, such as copepods, including copepods belonging to the family Caligidae, and oligonucleotide sequences comprising small nucleotide polymorphism (SNPs) associated therewith.
A method for the detection of resistance of pests to pyrethroid chemotherapeutics in particu!ar to a method of determining single polymorphisms associated with pyrethroid resistance in the mitochondrial DNA of arthropods, in particular crustaceans, in particular copepods, and the use of such SNP's in a screening method for determining whether such pests are sensitive to, or resistant to, pyrethroids.
The present invention relates to a method of forming a desired pattern on a substrate comprising the steps of a) generating an atomic or molecular beam, in particular a beam of He atoms; b) providing a mask having a desired pattern such as a Fourier transform of the desired pattern on the substrate; c) directing the atomic or molecular beam through the patterned mask onto a substrate, whereby a pattern is formed on the substrate by interaction with the proportion of the atomic or molecular beam which penetrates through the mask, which pattern is based on the pattern of the mask, wherein the patterned mask is prepared by a method comprising d) providing a porous starting mask material having openings of a size which allow the atomic or molecular beam to penetrate through; e) creating the desired pattern on the mask by filling a proportion of the openings of the mask which thereby become non-transparent for the atomic or molecular beam. The method of the present invention is useful for preparing conducting circuit structures (micro-chips) or microelectromechanical systems (MEMS) or structures for micro/nano fluidics or nanostructured surfaces in general, ie. hydrophobic or hydrophilic surfaces or reflective/antireflective surfaces.
G03F 1/00 - Originals for photomechanical production of textured or patterned surfaces, e.g. masks, photo-masks or reticlesMask blanks or pellicles thereforContainers specially adapted thereforPreparation thereof
G03F 1/20 - Masks or mask blanks for imaging by charged particle beam [CPB] radiation, e.g. by electron beamPreparation thereof
The present invention refers to novel ruthenium- and osmium-based catalysts for olefin metathesis reactions, particularly to catalysts having stereoselective properties. Z-selectivity is obtained by utilizing two mono-anionic ligands of very different steric requirement. In olefin metathesis reactions these catalysts selectively provide the Z-isomer of disubstituted olefinic products.
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (USA)
Inventor
Puntervoll, Pål
Sommerfelt, Halvor
Clements, John
Nataro, James, P.
Zhang, Weiping
Taxt, Arne, M.
Abstract
A mutant of an E coli heat-stable toxin (ST) having the following wild-type sequence: NSSNYCCELCCNPACTGCY wherein the mutant comprises a mutation selected from the group consisting of: A14H, A14T and N12T.
Image data (1) is filtered by determining, for each of a first plurality of points (4, 5) within the image data, which of a plurality of directions is the direction along which a line of samples containing the point has the least variation according to a predetermined measure of variation. This generates data representing a vector field. For each of a second plurality of points (4, 5) within the image data, (i) the vector field is integrated to determine a streamline or streamline segment from the point, and (ii) a filtered value for the point is determined by applying a filtering operation to the image data using a filtering kernel oriented along the streamline or streamline segment.
This invention relates to the use of a tunicate or an extract obtained from a tunicate for the production of one or more biofuel selected from an alcohol and biodiesel. The invention also relates to a method for producing a biofuel from a tunicate wherein the biofuel is selected from an alcohol and biodiesel and wherein said method comprises the steps of: (a)(i) subjecting said tunicate or one or more polysaccharides extracted from said tunicate to enzymatic or acid hydrolysis to form a hydrolysate containing one or more monosaccharides and (ii) fermenting said one or more monosaccharides to form an alcohol; or (b)(i) extracting lipids/fatty acids from said tunicate and (ii) converting said lipids/fatty acids into biodiesel by transesterification or alcoholysis or (iii) subjecting said tunicate to transesterification or alcoholysis thereby converting lipids/fatty acids present in said tunicate into biodiesel.
C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
C07C 29/09 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
C07C 29/147 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
Animal feeds and feed components are provided which comprise tunicate material. The tunicate material may be whole tunicate, e.g. washed and/or dried, or a tunicate extract. Preferred tunicate extracts include protein- and/or lipid-enhanced extracts. Also provided are uses of tunicates and tunicate extracts as, or in, animal feeds and methods for feeding animals, e.g. fish, comprising administering feeds containing tunicate material.
A23K 10/20 - Animal feeding-stuffs from material of animal origin
A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
Animal feeds and feed components are provided which comprise tunicate material. The tunicate material may be whole tunicate, e.g. washed and/or dried, or a tunicate extract. Preferred tunicate extracts include protein- and/or lipid-enhanced extracts. Also provided are uses of tunicates and tunicate extracts as, or in, animal feeds and methods for feeding animals, e.g. fish, comprising administering feeds containing tunicate material.
The present invention relates in a first aspect to new nucleic acid molecules and peptides identifying and diagnosing diarrhea syndrome including chronic diarrhea and bowel diseases. In addition, methods are provided for identifying or diagnosing a potential risk for developing or having a diarrhea syndrome comprising identifying in a sample from a subject the presence or absence of a mutation at position 2519 of the gene encoding GC-C. Moreover, a kit is provided allowing identification or diagnosing a diarrhea syndrome including probes allowing the detection of mutations at position 2519 of the nucleic acid sequence encoding GC-C or for detecting a mutation at position 840 of GC-C. Moreover, a method for screening and/or identifying candidate molecules useful in prophylactically or therapeutically treating said diseases is provided. Finally, the present invention relates to metformin and/or a pharmaceutically acceptable salts thereof for use in the prophylactic or therapeutic treatment of diarrhea syndrome.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention refers to novel ruthenium- and osmium-based catalysts for olefin metathesis reactions, particularly to catalysts having stereoselective properties. Z-selectivity is obtained by utilizing two mono-anionic ligands of very different steric requirement. In olefin metathesis reactions these catalysts selectively provide the Z-isomer of disubstituted olefinic products.
Fish lice treatment method The present invention provides methods for treating ectoparasitic infections in fish, especially fish lice infections in farmed salmon. Particulate lime is contacted with water housing the ectoparasites and, optionally, their host fish in an amount and for a time sufficient to detach and/or kill the ectoparasites.
The present invention relates to a method for diagnosis of different stages of endometrial cancer in an individual. Further, the present invention relates to a method for evaluating the probability of survival for an individual suffering from endometrial carcinoma. In another aspect, the present invention relates to the stratification of therapy regimen of endometrial tumor, ovarian cancer, breast cancer, non-small lung cancer or hormone refractory prostate cancer therapy in an individual or monitoring therapeutic efficacy in an individual suffering from the same based on the expression status of STMN1 gene or protein. Moreover, the present invention relates to a kit for use in any of the above referenced methods comprising a means for determining amplifications and deletions of chromosomal regions 3q26.32 and 12p12.1, determining alterations of the gene expression profile of the genes (gene signature): upregulation of the genes PLEKHK1, ATP10B, NMU, MMP1, ATAD2, NETO2, TNNI3, PHLDA2, OVOL1 and down-regulation of the genes: NDP, KIAA1434, MME, CFH, MOXD1, SLC47A1, RBP1, PDE8B, ASRGL1, ADAMTS19, EFHD1, ABCA5, NPAS3, SCML1, TNXB, ENTPD3, AMY1A, ENPP, RASL11B, PDZK3, or the expression status of the STMN1 gene or protein, respectively. Finally, the present invention provides a method for predicting the response to taxanes in an individual suffering from a disease treated with the taxanes based on the expression status of the STMN1 gene or protein.
The present invention refers to novel ruthenium- and osmium-based catalysts for olefin metathesis reactions, particularly to catalysts having stereoselective properties. Z-selectivity is obtained by utilising two mono-anionic ligands of very different steric requirement. In olefin metathesis reactions these catalysts selectively provide the Z-isomer of disubstituted olefinic products.
A method for determining a prognosis for survival for a patient with leukaemia is described. Also described is a method for monitoring the effectiveness of a course of treatment for a patient with leukaemia, and the use of such a method in a kit. A kit determining the level of RINF is also described.
This invention relates to the use of a tunicate or an extract obtained from a tunicate for the production of one or more biofuel selected from an alcohol and biodiesel. The invention also relates to a method for producing a biofuel from a tunicate wherein the biofuel is selected from an alcohol and biodiesel and wherein said method comprises the steps of: (a)(i) subjecting said tunicate or one or more polysaccharides extracted from said tunicate to enzymatic or acid hydrolysis to form a hydrolysate containing one or more monosaccharides and (ii) fermenting said one or more monosaccharides to form an alcohol; or (b)(i) extracting lipids/fatty acids from said tunicate and (ii) converting said lipids/ fatty acids into biodiesel by transesterification or alcoholysis or (iii) subjecting said tunicate to transesterification or alcoholysis thereby converting lipids/ fatty acids present in said tunicate into biodiesel.
This invention relates to the use of a tunicate or an extract obtained from a tunicate for the production of one or more biofuel selected from an alcohol and biodiesel. The invention also relates to a method for producing a biofuel from a tunicate wherein the biofuel is selected from an alcohol and biodiesel and wherein said method comprises the steps of: (a)(i) subjecting said tunicate or one or more polysaccharides extracted from said tunicate to enzymatic or acid hydrolysis to form a hydrolysate containing one or more monosaccharides and (ii) fermenting said one or more monosaccharides to form an alcohol; or (b)(i) extracting lipids/fatty acids from said tunicate and (ii) converting said lipids/ fatty acids into biodiesel by transesterification or alcoholysis or (iii) subjecting said tunicate to transesterification or alcoholysis thereby converting lipids/ fatty acids present in said tunicate into biodiesel.
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
58.
One-step conversion of solid lignin to liquid products
C07C 37/54 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions decreasing the number of carbon atoms by splitting polyaromatic compounds, e.g. polyphenolalkanes by hydrolysis of lignin or sulfite waste liquor
The invention relates to a method of recovering oil from a heterogeneous reservoir, comprising a plurality of permeable porous blocks of rock whose pores contain oil and which form interfaces with regions between the blocks, e.g. fractures, having a higher permeability than the blocks. The method comprises the steps of treating the interfaces such that the wettability of the surfaces of the blocks is in a predetermined wettability range, then reducing the permeability in the highly permeable regions, and finally flooding the reservoir by injecting a chase fluid into the reservoir. With the inventive method water phase bridges are established between adjacent blocks in the reservoir thus allowing a transmission of injection pressure for viscous displacement from one block to the next across the reservoir. The invention also relates to a method for long-time storage of CO2 by using CO2 as chase fluid or foaming gas according to the inventive method for oil recovery from heterogeneous reservoirs.
A method of enhanced oil recovery of remaining reservoir oil (1) from a subterranean geological reservoir (2), which has been subjected to at least one of a primary oil recovery and a secondary oil recovery, said enhanced oil recovery method comprises the steps of oil flooding the geological reservoir (2) using flooding oil (3), and recovering the reservoir oil (1) from the geological reservoir (2). Preferably, the flooding oil (3) comprises heavy crude oil being recovered from another geological reservoir. Furthermore, the invention comprises using heavy crude oil (3) for oil flooding a subterranean geological reservoir (2) and enhanced oil recovery from the geological reservoir (2).
A method of creating a carbon dioxide hydrate is disclosed. The preferred steps include supplying liquid carbon dioxide and a dissociation agent to a hydrocarbon hydrate, decomposing the hydrocarbon hydrate by the dissociation agent into a hydrocarbon gas and liquid water, and forming the carbon dioxide hydrate from the liquid carbon dioxide and the liquid water. The dissociation agent preferably is at least one of an inorganic salt, a surface active agent, a hydrate inhibitor, and an absorption solution. Furthermore, a substance composition of liquid carbon dioxide and the dissociation agent is described, which is provided for depositing carbon dioxide hydrate in a subterranean geological formation. Furthermore, a deposition device is described, which is configured for depositing carbon dioxide hydrate in a subterranean geological formation.
The present invention relates to novel uses of Hydroxyproline in a pharmaceutical or dietary food supplement composition for treating, ameliorating, or curing certain diseases and disorders in an individual in need thereof such as a human being, in particular diseases and disorders in tissues and organs having high levels of collagen and/or elastin, such as muscle and/or connective tissue, said tissues having high levels of collagen and/or elastin. The invention further relates to a food composition comprising hydroxyproline for feeding animals, such as fish, resulting in increased muscle strength, texture and firmness.
The present invention relates to the use of AxI as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject. More specifically, the invention relates to various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring AxI expression and/or activity.
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C 37/54 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions decreasing the number of carbon atoms by splitting polyaromatic compounds, e.g. polyphenolalkanes by hydrolysis of lignin or sulfite waste liquor
C10G 1/06 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal by destructive hydrogenation
C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
65.
BIOMOLECULE COMPLEXES AS CONTRAST AGENTS IN POSITRON EMISSION TOMOGRAPHY (PET) BASED METHODS FOR THE ASSESSMENT OF ORGAN FUNCTION
The present invention relates to complexes comprising one or more markers and one or more biomolecules for use as a contrast agent in positron emission tomography based imaging. The complexes according to the present invention preferably accumulate in a target compartment, such as the kidney. The present invention further relates to methods for generating the complexes and methods for using the complexes such as for evaluation of different aspects of kidney functionality e.g. for calculation of total and/or regional glomerular filtration rate in the kidney without the need for sampling blood or urine.
C07D 213/16 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
The present invention describes a novel retinoid-responsive nucleic acid, and a novel protein. Further, the invention describes the use of such a nucleic acid or protein in various diseases, and for the treatment, the diagnosis and prognosis of various diseases, and also for a method for the prognosis of responsiveness to retinoids.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
An image processing method is applied on an image of a target or on a segment thereof. A deconvolution procedure (S1) includes a blind deconvolution of the whole image or segment to estimate a point: spread function characterizing the imaging process and a target function characterizing the distribution of reflectors and scatterers in the target. The deconvolution is an iterative blind deconvolution. The target function and the point spread function are estimated and updated by alternating between two equations. At least one constraint is enforced at each iteration. An image processing unit (10) and an image processing apparatus (1) are also provided.
The present invention relates in a first aspect to a B-cell depleting anti-CD20 antibody or a CD20-binding antibody fragment thereof for the treatment of chronic fatigue syndrome and myalgic encephalomyelitis. In particular, the present invention relates to the use of anti-CD20 monoclonal antibodies or fragments thereof which are preferably humanized for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis in a subject afflicted with said disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
69.
ONE-STEP CONVERSION OF SOLID LIGNIN TO LIQUID PRODUCTS
The present invention refers to a method of converting a lignin material into a liquid product by treatment in a reaction medium comprising at least one C1-C2 carboxylic acid under devated temperature and pressure and the liquid product obtainable by the method.
C10G 1/00 - Production of liquid hydrocarbon mixtures from oil shale, oil-sand, or non-melting solid carbonaceous or similar materials, e.g. wood, coal
C07C 37/54 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions decreasing the number of carbon atoms by splitting polyaromatic compounds, e.g. polyphenolalkanes by hydrolysis of lignin or sulfite waste liquor
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
70.
PARAMAGNETIC BIOMOLECULE COMPLEXES AND USES THEREOF IN THE ASSESSMENT OF ORGAN FUNCTION
The present invention relates to complexes comprising one or more marker(s) and one or more biomolecules. The complexes according to the present invention have a variety of utilities, such as utility as a contrast agent in imaging methods, for example magnetic resonance imaging.
The invention concerns novel use for Hydroxyproline in a pharmaceutical or dietary food or feed compositions for promoting growth e.g. of fish and/or for treating, ameliorating, or curing certain disorders including osteoporosis, psoriasis, enteritis and gingivitis.
The present invention discloses a new process for the preparation of 1,4-benzoquiones of formula (II) wherein R1, R2, R3 and R4 are independently selected from the group consisting of H, branched or unbranched C1-C6 alkyl, phenyl and benzyl, wherein phenyl and benzyl is optionally substituted by one or more substituent independently selected from the group consisting of C1-C6 alkyl and halogen, and wherein C1-C6 alkyl is optionally substituted with one or more halogen susbstituents, and wherein R2 and R3 together can form a C1-C6-alkylene radical, optionally substituted by one or more susbstituents independently selected from the group comprising C1-C6 alkyl, benzyl, phenyl and halogen. One preferred compound is 2,3- dimethoxy-5-methyl-[l,4]benzoquinone, also known as coenzyme Q0 (CoQ0). Also disclosed are novel compounds and intermediates, and a method for the preparation of coenzyme Qn, preferable the coenzyme Q10. Also disclosed is a method for continuous synthesis of 1,4- benzoquiones in a continuous flow reactor.
The present invention relates to methods for the detection of EGFRvIII nucleic acid molecules. In particular, the present invention relates to PCR based methods for the detection of EGFRvIII in biological samples. In a further aspect, the present invention relates to detection kits for detecting EGFRvIII in biological samples. The present invention allows to identify specifically the expression of EGFRvIII nucleic acid molecules, in particular, of EGFRvIII RNA in individuals. Said methods and kits are particularly useful to determine and identify precancerous or cancerous lesions at early stages in individuals suspected to have cancer.
The present invention relates to cyanobacterial cyclic peptides and particularly to a novel nostocyclopeptide. The invention further provides a compound and a pharmaceutical composition comprising said nostocyclopeptide. The invention also discloses said nostocyclopeptide for use as a medicament as well as the use of nostocyclopeptide for the manufacture of a medicine for the treatment against hepato toxins.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
patents
